<p>东京和马萨诸塞州剑桥，2025 年 12 月 9 日 -（JCN Newswire）- 日本卫材株式会社（总部：东京，首席执行官：内藤晴夫，&#34;卫材&#34;）与 Biogen Inc.（纳斯达克股票代码：BIIB，企业总部：马萨诸塞州剑桥，首席执行官：克里斯托弗·A·维巴赫，&#34;Biogen&#34;）今天宣布，抗 Aβ原纤维抗体&#34;LEQEMBI(R)&#34;（通用名：lecanemab）已被纳入中国国家医疗保障局（NHSA）最近推出的&#34;商业保险创新药物清单&#34;。LEQEMBI 被纳入该清单标志着在中国扩大早期阿尔茨海默病（AD）治疗可及性的重要一步。</p>
<p>商业保险创新药物清单是基于中国政府的新政策，以支持创新药物的开发和获取。该清单旨在帮助缩小国家医保药品清单（NRDL）下的基本报销系统与满足重大未满足需求的创新药物之间的覆盖差距。根据商业保险创新药物清单，商业保险公司将与制药公司讨论并达成覆盖细节的协议，并开发针对列入清单药物的保险产品。商业保险创新药物清单计划于 2026 年 1 月 1 日生效。</p>
<p>卫材估计，2024 年中国有 1700 万名因阿尔茨海默病（AD）导致的轻度认知障碍（MCI）或轻度痴呆患者，预计随着人口老龄化这一数字将会增加。</p>
<p>卫材于 2024 年 6 月在中国推出 LEQEMBI，并已在私人市场上交付该产品。</p>
<p>卫材负责 LEQEMBI 的全球开发和监管提交，卫材与 Biogen 共同商业化和推广该产品，卫材拥有最终决策权。卫材将在中国分销该产品，并通过专业的医学代表进行信息提供活动。</p>
<p>* 原纤维被认为是导致阿尔茨海默病（AD）相关脑损伤的因素，并被视为 Aβ的最具毒性形式，在与这种渐进性、削弱性疾病相关的认知衰退中发挥着主要作用。原纤维对大脑中的神经元造成损伤，这反过来又可以通过多种机制对认知功能产生负面影响，不仅增加不溶性 Aβ斑块的发展，还直接损害大脑细胞膜以及传递神经细胞之间或神经细胞与其他细胞之间信号的连接。人们相信，减少原纤维可能通过减少对大脑神经元的损伤和认知功能障碍来防止阿尔茨海默病的进展。</p>
<p>媒体联系人</p>
<p>卫材</p>
<p>卫材株式会社</p>
<p>公共关系部</p>
<p>电话：+81 (0) 3-3817-5120</p>
<p>卫材欧洲有限公司</p>
<p>EMEA 通讯部</p>
<p>+44 (0) 7974-879-419</p>
<p>Emea-comms@eisai.net</p>
<p>卫材公司（美国）</p>
<p>利比·霍尔曼</p>
<p>+1-201-753-1945</p>
<p>Libby_Holman@eisai.com</p>
<p>Biogen Inc.</p>
<p>麦德琳·申</p>
<ul>
<li>1-781-464-3260</li>
</ul>
<p>public.affairs@biogen.com</p>
<p>投资者联系人</p>
<p>卫材株式会社</p>
<p>投资者关系部</p>
<p>电话：+81 (0) 3-3817-5122</p>
<p>Biogen Inc.</p>
<p>蒂姆·鲍尔</p>
<ul>
<li>1-781-464-2442</li>
</ul>
<p>IR@biogen.com</p>
<p>欲了解更多详情，请访问：https://www.eisai.com/news/2025/pdf/enews202586pdf.pdf</p>
<p>来源：卫材</p>
<p>版权 2025 JCN Newswire。保留所有权利。</p>

BIIB

<p>卫材株式会社和 Biogen 公司宣布，他们的药物 LEQEMBI（lecanemab）已被中国国家医疗保障局纳入商业保险创新药物名单。此举旨在扩大中国对创新药物的获取，满足重大未满足的需求。该名单将于 2026 年 1 月 1 日生效，便于保险公司与制药公司就覆盖细节进行讨论</p>

<p>TOKYO and CAMBRIDGE, Mass., Dec 9, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &#34;Eisai&#34;) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, &#34;Biogen&#34;) announced today that anti-Aβ protofibril* antibody &#34;LEQEMBI(R)&#34; (generic name: lecanemab), has been included in the &#34;Commercial Insurance Innovative Drug List&#34;, recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.</p>
<div class="lb-trans"><p>东京和马萨诸塞州剑桥，2025 年 12 月 9 日 -（JCN Newswire）- 日本卫材株式会社（总部：东京，首席执行官：内藤晴夫，&#34;卫材&#34;）与 Biogen Inc.（纳斯达克股票代码：BIIB，企业总部：马萨诸塞州剑桥，首席执行官：克里斯托弗·A·维巴赫，&#34;Biogen&#34;）今天宣布，抗 Aβ原纤维抗体&#34;LEQEMBI(R)&#34;（通用名：lecanemab）已被纳入中国国家医疗保障局（NHSA）最近推出的&#34;商业保险创新药物清单&#34;。LEQEMBI 被纳入该清单标志着在中国扩大早期阿尔茨海默病（AD）治疗可及性的重要一步。</p>
</div><p>The Commercial Insurance Innovative Drug List is based on new policies of the Chinese government to support the development and access of innovative medicines. The list aims to help narrow the coverage gap between the basic reimbursement system under the National Reimbursement Drug List (NRDL) and innovative medicines that address areas of significant unmet need. Based on the Commercial Insurance Innovative Drug List, Commercial insurance companies will discuss and reach the agreement with pharmaceutical companies regarding coverage details, and develop insurance products focusing on the listed medicines. The Commercial Insurance Innovative Drug List is scheduled to take effect on January 1, 2026.</p>
<div class="lb-trans"><p>商业保险创新药物清单是基于中国政府的新政策，以支持创新药物的开发和获取。该清单旨在帮助缩小国家医保药品清单（NRDL）下的基本报销系统与满足重大未满足需求的创新药物之间的覆盖差距。根据商业保险创新药物清单，商业保险公司将与制药公司讨论并达成覆盖细节的协议，并开发针对列入清单药物的保险产品。商业保险创新药物清单计划于 2026 年 1 月 1 日生效。</p>
</div><p>Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population.</p>
<div class="lb-trans"><p>卫材估计，2024 年中国有 1700 万名因阿尔茨海默病（AD）导致的轻度认知障碍（MCI）或轻度痴呆患者，预计随着人口老龄化这一数字将会增加。</p>
</div><p>Eisai launched LEQEMBI in China in June 2024 and has delivered the product in the private market.</p>
<div class="lb-trans"><p>卫材于 2024 年 6 月在中国推出 LEQEMBI，并已在私人市场上交付该产品。</p>
</div><p>Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.</p>
<div class="lb-trans"><p>卫材负责 LEQEMBI 的全球开发和监管提交，卫材与 Biogen 共同商业化和推广该产品，卫材拥有最终决策权。卫材将在中国分销该产品，并通过专业的医学代表进行信息提供活动。</p>
</div><p>*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2</p>
<div class="lb-trans"><p>* 原纤维被认为是导致阿尔茨海默病（AD）相关脑损伤的因素，并被视为 Aβ的最具毒性形式，在与这种渐进性、削弱性疾病相关的认知衰退中发挥着主要作用。原纤维对大脑中的神经元造成损伤，这反过来又可以通过多种机制对认知功能产生负面影响，不仅增加不溶性 Aβ斑块的发展，还直接损害大脑细胞膜以及传递神经细胞之间或神经细胞与其他细胞之间信号的连接。人们相信，减少原纤维可能通过减少对大脑神经元的损伤和认知功能障碍来防止阿尔茨海默病的进展。</p>
</div><p>MEDIA CONTACTS</p>
<div class="lb-trans"><p>媒体联系人</p>
</div><p>Eisai</p>
<div class="lb-trans"><p>卫材</p>
</div><p>Eisai Co., Ltd.</p>
<div class="lb-trans"><p>卫材株式会社</p>
</div><p>Public Relations Department</p>
<div class="lb-trans"><p>公共关系部</p>
</div><p>TEL: +81 (0) 3-3817-5120</p>
<div class="lb-trans"><p>电话：+81 (0) 3-3817-5120</p>
</div><p>Eisai Europe, Ltd.</p>
<div class="lb-trans"><p>卫材欧洲有限公司</p>
</div><p>EMEA Communications Department</p>
<div class="lb-trans"><p>EMEA 通讯部</p>
</div><p>+44 (0) 7974-879-419</p>
<div class="lb-trans"><p>+44 (0) 7974-879-419</p>
</div><p>Emea-comms@eisai.net</p>
<div class="lb-trans"><p>Emea-comms@eisai.net</p>
</div><p>Eisai Inc. (U.S.)</p>
<div class="lb-trans"><p>卫材公司（美国）</p>
</div><p>Libby Holman</p>
<div class="lb-trans"><p>利比·霍尔曼</p>
</div><p>+1-201-753-1945</p>
<div class="lb-trans"><p>+1-201-753-1945</p>
</div><p>Libby_Holman@eisai.com</p>
<div class="lb-trans"><p>Libby_Holman@eisai.com</p>
</div><p>Biogen Inc.</p>
<div class="lb-trans"><p>Biogen Inc.</p>
</div><p>Madeleine Shin</p>
<div class="lb-trans"><p>麦德琳·申</p>
</div><p>+ 1-781-464-3260</p>
<div class="lb-trans"><ul>
<li>1-781-464-3260</li>
</ul>
</div><p>public.affairs@biogen.com</p>
<div class="lb-trans"><p>public.affairs@biogen.com</p>
</div><p>INVESTOR CONTACTS</p>
<div class="lb-trans"><p>投资者联系人</p>
</div><p>Eisai Co., Ltd.</p>
<div class="lb-trans"><p>卫材株式会社</p>
</div><p>Investor Relations Department</p>
<div class="lb-trans"><p>投资者关系部</p>
</div><p>TEL: +81 (0) 3-3817-5122</p>
<div class="lb-trans"><p>电话：+81 (0) 3-3817-5122</p>
</div><p>Biogen Inc.</p>
<div class="lb-trans"><p>Biogen Inc.</p>
</div><p>Tim Power</p>
<div class="lb-trans"><p>蒂姆·鲍尔</p>
</div><p>+ 1-781-464-2442</p>
<div class="lb-trans"><ul>
<li>1-781-464-2442</li>
</ul>
</div><p>IR@biogen.com</p>
<div class="lb-trans"><p>IR@biogen.com</p>
</div><p>For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202586pdf.pdf</p>
<div class="lb-trans"><p>欲了解更多详情，请访问：https://www.eisai.com/news/2025/pdf/enews202586pdf.pdf</p>
</div><p>Source: Eisai</p>
<div class="lb-trans"><p>来源：卫材</p>
</div><p>Copyright 2025 JCN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 2025 JCN Newswire。保留所有权利。</p>
</div>

"LEQEMBI(R)" (lecanemab) 用于治疗早期阿尔茨海默病被纳入中国商业保险的创新药物清单